BioSpring to build three oligonucleotide API production units in Offenbach, Germany

BioSpring acquired 30,000 sq m of land in Offenbach, Germany to build three new production units for oligonucleotide-based active pharmaceutical ingredients. The company plans to invest over €100 million and create 1,500 jobs.

“BioSpring plans to invest upwards of €100 million ($106 million) and create 1,500 jobs in the long run.”endpoints.news

• 1 source
• endpoints.newsBioSpring invests €100M+ into new oligonucleotide API facilities in GermanyTyler PatchenDec 21, 2022

Summarized from public sources; check the original articles before acting on it.